2021 Satellite CME Symposiums

Thursday, September 9, 2021, from 6:00 – 7:00 pm CT
Management of Hyperlipidemia in the Family Medicine Setting: Diagnosis, Management and the Role of Emerging Lipid-lowering Therapies
Presented by James A. Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA Lipidology & Cardiovascular Disease Prevention, Diplomate American Board of Clinical Lipidology, Clinical Assistant Professor of Medicine NYU Medical School & NYU Center for CV Prevention, Director, Bellevue Hospital Lipid Clinic, Past-President National Lipid Association President American Board of Clinical Lipidology, New York, New York
Educational Objectives:
Upon completion of this activity, participants should be better able to:
•    Summarize the diagnostic evaluation and current clinical guidelines for the treatment of hyperlipidemia
•    Identify the mechanisms of action and safety-efficacy data of currently available and emerging investigational lipid-lowering therapies
•    Employ available clinical evidence to recognize patients who may benefit from emerging PCSK9-targeting therapies
•    Evaluate the role of multidisciplinary collaboration and patient education to optimize outcomes in patients with hyperlipidemia.
Dr. Underberg is a Clinical Lipidologist. He is a Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease. He is also the Director of the Bellevue Hospital Lipid Clinic. Dr. Underberg holds joint appointments in the divisions of General Internal Medicine and Endocrinology at NYU.  Dr. Underberg is a Diplomate of the American Board of Clinical Lipidology and Past President of the National Lipid Association.  He is a Fellow of the National Lipid Association , President of the American Board of Clinical Lipidology & Vice President of the Foundation of the National Lipid Association. He serves on the editorial board of the Journal of Clinical Lipidology and is a board member of the Foundation of the National Lipid Association and the American Board of Clinical Lipidology. Dr. Underberg’s Clinical Interests focus on the clinical management of patients with lipids and lipoprotein disorders and cardiovascular disease prevention. He maintains an active clinical research program in these areas and has authored numerous articles and book chapters in the field of Clinical Lipidology. He sees patients both at Bellevue Hospital and in a University based Private practice setting.
Sponsored by PeerView Institute for Medical Education. This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Friday, September 10, 2021 from 10:30 – 11:30 am    
Focus on Overactive Bladder: A Fine-Tuned Approach to Attain Outcome Targets
Presented by Patrick J. Shenot, MD, Professor of Urology, Residency Program Director, Deputy Chair, Department of Urology at Thomas Jefferson University, Philadelphia, PA
 Learning Objectives:
•    Upon completing this activity, participants will be able to:
•    Proactively evaluate and screen at-risk individuals for overactive bladder (OAB)
•    Utilize communication strategies aimed to evaluate the impact of OAB on quality of life and educate patients on appropriate treatment options and expectations
•    Select patients with OAB who would benefit from combination therapy to maximize efficacy and tolerability
1.    The Initial Patient Evaluation and Screening
2.    Identifying the at-risk population
3.    Initiating the conversation about OAB
4.    Making the differential diagnosis
5.    Treatment Selection to Optimize Efficacy and Tolerability
6.    AUA/SUFU guideline recommendations
7.    Implementing a treat-to-target approach
8.    Evaluating patient outcomes and expectations
9.    Managing adverse effects
10.  Selecting patients for combination therapy
Jointly provided by Center for Independent Healthcare Education and VemcoMedEd. Supported by an educational grant from Astellas Scientific and Medical Affairs, Inc.

Saturday, September 11, 2021, from 7:45 – 8:45 am    
Overcoming Challenges in the Diagnosis and Management of Axial Spondyloarthritis: New Insights and Implications for Clinical Practice
Presented by Abhijeet Danve, MD, FACP, FACR, Assistant Professor of Clinical Medicine, Director Spondyloarthritis Clinic, Yale School of Medicine, New Haven, Connecticut
Educational Objectives:
Upon completion of this activity, participants should be better able to:
•    Identify axSpA in patients with inflammatory back pain via assessment of medical history, musculoskeletal symptoms and findings, and extra-articular manifestations and comorbidities
•    Apply classification criteria and diagnostic tests into clinical practice to support early detection of axSpA
•    Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies
•    Employ treatment plans for individual patients with axSpA in accordance with current evidence, expert recommendations, and patient needs and preferences
•    Recognize the importance of collaborating with rheumatologists to provide optimal treatment and longitudinal support for patients with axSpA
Dr. Abhijeet Danve is rheumatologist and Assistant Professor of Clinical Medicine at Yale University, New Haven CT with particular interest in clinical and translational research focused on early diagnosis of axial spondyloarthritis (axSpA). He is founding director of spondyloarthritis program at Yale. Dr. Danve has contributed original research articles, systematic reviews and review articles in the field of axSpA and his publications in reputed journals cover various aspects of axSpA such as biomarkers, screening and referral, treat to target strategy, role of complementary medicine and comorbidities.  He is member of Spondyloarthritis Research and Treatment Network (SPARTAN), and serves on Registry subcommittee of SPARTAN since 2017. Prior to joining Yale, Dr. Danve completed his clinical rheumatology fellowship at Oregon Health and Sciences University, Portland, OR and research fellowship at University of Nebraska Medical Center. Dr. Danve is recipient of Marshall J Schiff Memorial research award (2013) and Distinguished Fellow award (2015) given by American College of Rheumatology. He lives in Rocky Hill CT with his wife Supriya and 2 boys. He loves to travel and has keen interest in Indian classical music.

General research focus and recent work- His current research is focused on early diagnosis of axSpA by applying efficient and cost-effective screening and referral strategies. Dr. Danve has developed an online clinical screening tool for early identification of axSpA and he is conducting a funded clinical research study to evaluate its effectiveness. He is also trying to find new biomarkers for diagnosis of axSpA. Dr. Danve has developed a comprehensive multidisciplinary spondyloarthritis program at Yale consisting rheumatologist, dermatologist, gastroenterologist, physical therapist and orthopedist which with aim of providing excellent care to axSpA patients and conducting high quality clinical and translational research. He is also interested in collecting patient reported outcomes and disease activity measures electronically using iPADs and integrate those into EMR for improving the quality of care delivery for axSpA.
Sponsored by PeerView Institute for Medical Education. This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.